MiR-506 inhibits cell proliferation, invasion, migration and epithelial-to-mesenchymal transition through targeting RWDD4 in human bladder cancer.
RWDD4
bladder cancer
epithelial-to-mesenchymal transition
miR-506
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
22
01
2018
accepted:
12
04
2018
entrez:
19
1
2019
pubmed:
19
1
2019
medline:
19
1
2019
Statut:
ppublish
Résumé
MicroRNA (MiR)-506 serves a vital role in several types of cancer. However, the role of miR-506 in bladder cancer (BCa) progression remains to be investigated. The present study demonstrated that miR-506 expression was downregulated in BCa tissues and cell lines. Meanwhile, overexpression of miR-506 inhibited cell proliferation, migration and invasion. Additionally, upregulated miR-506 increased E-cadherin, and reduced N-cadherin and Vimentin expression levels, as markers of epithelial-to-mesenchymal transition. RWD domain containing 4 (RWDD4) was revealed to be a miR506 target in BCa cells, and the downregulation of RWDD4 was found to suppress BCa cell proliferation, migration and invasion. In summary, miR-506 may suppress the aggressive properties of human BCa cells by targeting RWDD4, and thus may be a novel therapeutic target in human BCa.
Identifiants
pubmed: 30655740
doi: 10.3892/ol.2018.9594
pii: OL-0-0-9594
pmc: PMC6313135
doi:
Types de publication
Journal Article
Langues
eng
Pagination
73-78Références
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Nat Rev Cancer. 2007 Jun;7(6):415-28
pubmed: 17508028
Cancer Res. 2008 May 15;68(10):3645-54
pubmed: 18483246
Nat Rev Cancer. 2009 Apr;9(4):265-73
pubmed: 19262571
Mol Cell Pharmacol. 2010;2(5):213-219
pubmed: 21289871
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Oncogene. 2012 Mar 22;31(12):1558-70
pubmed: 21860416
Semin Cancer Biol. 2012 Oct;22(5-6):396-403
pubmed: 22554795
PLoS One. 2013 May 22;8(5):e64273
pubmed: 23717581
Eur Urol. 2014 Jul;66(1):42-54
pubmed: 24018020
Annu Rev Pathol. 2014;9:287-314
pubmed: 24079833
Oncogene. 2015 Feb 5;34(6):691-703
pubmed: 24469051
J Pathol. 2014 Jul;233(3):308-18
pubmed: 24604117
Oncogene. 2015 Feb 5;34(6):717-25
pubmed: 24608427
Trends Mol Med. 2014 Aug;20(8):460-9
pubmed: 25027972
Adv Biol Regul. 2015 Jan;57:1-9
pubmed: 25294678
Eur Urol. 2016 Jun;69(6):984-7
pubmed: 26194042
Mol Med Rep. 2015 Oct;12(4):5121-6
pubmed: 26238203
Investig Clin Urol. 2016 Jun;57 Suppl 1:S60-76
pubmed: 27326409
Nat Rev Urol. 2016 Dec;13(12):734-752
pubmed: 27804986
Cell Syst. 2017 Jan 25;4(1):31-45.e6
pubmed: 27916600
Chin J Cancer. 2017 Jan 21;36(1):16
pubmed: 28109319
Chin J Cancer. 2017 Apr 3;36(1):38
pubmed: 28372569
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
Mol Med Rep. 2017 Oct;16(4):3894-3900
pubmed: 28731159